JNJ J&j RESULTS: Q2, Q2 ADJ EPS $2.90 vs EST $2.85, Q2 sales $25.31B vs EST $25.05B, Q2 darzalex worldwide sales $4.21B, Q2 stelara worldwid
JNJ J&j RESULTS: Q2, Q2 ADJ EPS $2.90 vs EST $2.85, Q2 sales $25.31B vs EST $25.05B, Q2 darzalex worldwide sales $4.21B, Q2 stelara worldwide sales $740M; tremfya worldwide sales $2.05B, J&j Earnings Notes:, Outlook FY ADJ EPS $11.60–$11.75 vs EST $11.59, Outlook FY operational sales $100.3B–$100.9B vs EST $101.05B, On track to meet 2026 target of more than $100B in annual REV, In Q2 2026, commenced supply chain restructuring program primarily in innovative Medicine segment to exit some manufacturing locations, Supply chain restructuring program to be substantially completed by FY2029-end with ESTd costs between $650M-$750M, $200M restructuring expenses, primarily related to asset impairments, recorded in Q2 2026
JNJ J&j RESULTS: Q2, Q2 ADJ EPS $2.90 vs EST $2.85, Q2 sales $25.31B vs EST $25.05B, Q2 darzalex worldwide sales $4.21B, Q2 stelara worldwide sales $740M; tremfya worldwide sales $2.05B, J&j Earnings Notes:, Outlook FY ADJ EPS $11.60–$11.75 vs EST $11.59, Outlook FY operational sales $100.3B–$100.9B vs EST $101.05B, On track to meet 2026 target of more than $100B in annual REV, In Q2 2026, commenced supply chain restructuring program primarily in innovative Medicine segment to exit some manufacturing locations, Supply chain restructuring program to be substantially completed by FY2029-end with ESTd costs between $650M-$750M, $200M restructuring expenses, primarily related to asset impairments, recorded in Q2 2026